Denali Capital Pursues Alternatives After Longevity Merger Ends

Denali Capital Acquisition Corp. Class A (DECA) has provided an announcement.

Denali Capital Acquisition Corp. has terminated its Merger Agreement with Longevity Biomedical, Inc., and related subsidiaries, initially established in January 2023. Following this termination, Denali is exploring alternative business combination opportunities. This decision has also led to the withdrawal of a registration statement previously submitted to the SEC. Details of the termination have been outlined in a press release, but the contents are not considered legally filed or materially altering previous SEC filings by Denali.

For detailed information about DECA stock, go to TipRanks’ Stock Analysis page.